Myeloablative doses of yttrium‐90‐ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia

Abstract

Because the long-term toxicity of myeloablative radioimmunotherapy remains a matter of concern, the authors evaluated the hematopoietic damage and incidence of secondary myelodysplastic syndrome and acute myelogenous leukemia (sMDS/AML) in patients who received myeloablative doses of the radiolabeled antibody yttrium-90 (⁹⁰Y)-ibritumomab tiuxetan

Upfront Consolidation Combining Yttrium-90 Ibritumomab Tiuxetan and High-Dose Therapy with Stem Cell Transplantation in Poor-Risk Patients with Diffuse Large B Cell Lymphoma

“…So far, no secondary malignancies occurred, but long-term follow-up is needed for a complete safety report. Previous analysis in patients treated with Y 90 ibritumomab did not show an increased risk of secondary malignancies [40]. Dose-escalated Y 90 elabeled ibritumomab tiuxetan may be safely combined with BEAM and has the potential to be more effective than standard dose, but it requires careful dosimetry [14].…”

Consolidation of first remission using radioimmunotherapy with yttrium-90-ibritumomab-tiuxetan in adult patients with Burkitt lymphoma

“…One malignancy was observed within the non-Y-90-IT patient group [12]; one patient was diagnosed with colon carcinoma 2.8 years after BL diagnosis. No secondary malignancies were so far observed in the Y-90-IT treated patients.…”

Therapy-related myelodysplastic syndromes, or are they?

“…t-MDS/AML after RIT as part of myeloablative regimen has been reported (8% at 5 years) but the incidence does not seem to be increased when compared with patients treated with chemotherapy-based myeloablative regimens [33]. Follow up data from several studies suggest that the use of RIT in the non-transplant setting is associated with increased risk of t-MDS/AML [34,35].…”